BioSpace News Archive

Culture Biosciences today announced the formation of its inaugural Advisory Board.

IMPACT Therapeutics and Eikon Therapeutics today announced that the companies have entered into a global license and collaboration agreement for PARP1 selective inhibitors including IMP1734, which is anticipated to enter into Phase I clinical study in 2023.

YS Biopharma Co., Ltd. today announced that its PIKA Rabies Vaccine (the “Vaccine”) was granted Phase 3 clinical trial approval from the Food and Drug Administration of the Philippines.

RenovoRx, Inc today announced that the University of Texas (UT) Southwestern Medical Center is now enrolling pancreatic cancer patients in the open label, randomized Phase III TIGeR-PaC clinical trial.

Vistagen today announced that positive safety and exploratory efficacy data from its large Phase 3 open-label study of fasedienol (PH94B) nasal spray for the treatment of anxiety in adults with social anxiety disorder (SAD) were presented in a late-breaking poster presentation at the American Society for Clinical Psychopharmacology (ASCP) 2023 Annual Meeting taking place in Miami from May 30 through June 2, 2023.

Palisade Bio, Inc. today announced that J.D. Finley has been named Chief Executive Officer (CEO), effective today.

Evofem Biosciences, Inc. (OTCQB: EVFMD) today announced strong preliminary results for the first quarter of 2023, including robust growth in net product sales of its hormone-free prescription contraceptive gel, Phexxi® (lactic acid, citric acid and potassium bitartrate).

Excision BioTherapeutics, Inc., a clinical-stage biotechnology company developing CRISPR-based therapies designed to cure viral infectious diseases, today announced the appointment of Jeffrey B. Kindler, former Chairman and Chief Executive Officer (CEO) of Pfizer and current CEO of Centrexion Therapeutics, to its Board of Directors.

ALR Technologies SG Ltd., the diabetes management company, announces the issuance of a purchase order for the first shipment of second generation CGM hardware used in the GluCurve Pet CGM.

Penumbra, Inc. announced the U.S. Food and Drug Administration clearance and launch of Lightning Bolt™ 7, the most advanced and powerful arterial thrombectomy system on the market.